We genotyped members of a large family with apparent autosomal dominant FSGS using a dense set of SNP markers (Affymetrix 250K SNPChip array) followed by focused microsatellite genotyping. We identified a locus for FSGS in this family on 14q32 (family FGJN, [Figure 1](#F1){ref-type="fig"} and [Supplementary Figure 2](#SD1){ref-type="supplementary-material"}). This region overlapped with a larger locus that we previously identified by linkage analysis in another large family with a similar clinical course (family FGBR, [Figure 1](#F1){ref-type="fig"} and [Supplementary Figure 2](#SD1){ref-type="supplementary-material"}). We suspected that FSGS in both families was caused by a defect in the same gene. Under this assumption, the critical region was defined by flanking SNPs rs3783397 (at approximately 103 Mb on the Marshfield map) and rs6576201 (at approximately 106 Mb).

We used public databases to identify genes in this region. We sequenced 15 genes in affected members of the FGBR and FGJN families. We found a sequence variant in each family within the same exon of *INF2* that segregated with disease and predicted a non-conservative amino-acid change (R218Q in FGJN and S186P in FGBR). We observed no significant sequence variants in the other genes analyzed. The R218Q variant found in family FGJN was a *de novo* mutation, as the first individual in the family carrying this R218Q variant shared the disease associated haplotype, but not this variant, with several unaffected siblings (not shown).

We then sequenced *INF2* in 91 unrelated individuals with familial FSGS. In probands from nine additional families, we identified point mutations leading to non-conservative amino acid changes ([Table 1](#T1){ref-type="table"}, [Figure 2a](#F2){ref-type="fig"}, and [Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). We typed these variants in available family members. We considered a family member to be affected if he/she had biopsy-proven FSGS, ESRD without other apparent cause, or significant albuminuria without other apparent cause (\> 250 mg albumin per gram creatinine). We found that these mutations segregated with disease in their respective families ([Figure 1](#F1){ref-type="fig"} and [Supplementary Figure 2](#SD1){ref-type="supplementary-material"}). In five families, some younger individuals carrying these point mutations had no increase in urine protein, consistent with reduced, age-related penetrance, similar to the phenotypes associated with *TRPC6* and *ACTN4* mutations[@R1]--[@R3]. We found nucleotide variants in exons 8, 18, and 20, but these did not segregate with disease and were found in control individuals. All of the disease segregating mutations are located within the region of INF2 known as the diaphanous-inhibitory domain, or DID ([Figure 2b](#F2){ref-type="fig"}), and most reside within exon 4[@R4].

To be certain that these variants were not polymorphisms, and to be certain that the *INF2* gene is not a site of frequent but biologically insignificant variation, we resequenced exon 4, the location of all but two of the putative mutations, in 282 control individuals. None of these individuals carried any of these putative disease-causing *INF2* variants, nor any other missense or splicing variation. We genotyped the two putative disease-causing mutations found in exon 2 (A13T, L42P) as well as the E184K and R218Q mutations in an additional 341 control individuals using Sequenom assays. Neither variant was present in any of the 682 chromosomes assayed.

The phenotype in families with INF2 mutations shares certain features. Unlike the early onset, nephrotic presentation seen with mutations in the slit-diaphragm proteins nephrin and podocin, these individuals presented in early adolescence or adulthood, typically with moderate proteinuria. While we documented nephrotic range proteinuria in members of several of these families, none of the affected individuals displayed the spectrum of clinical findings that constitutes the so-called nephrotic syndrome. Microscopic hematuria and hypertension were noted in some affected individuals. Similar to patients with mutations in ACTN4, disease and proteinuria were progressive, often leading to end-stage renal disease (ESRD).

We reviewed available renal biopsy tissue samples from individuals with *INF2* mutations. Light microscopy typically showed FSGS ([Figure 3a](#F3){ref-type="fig"}). In these biopsies, electron microscopy showed focal areas of podocyte foot process effacement, typical of secondary and some genetic forms of FSGS, as well as areas where foot processes and slit-diaphragms were well preserved. We also noted unusually prominent actin bundles within the foot processes ([Figure 3b](#F3){ref-type="fig"}). Glomerular hypertrophy was not a prominent feature of the biopsies. Neither we nor the original pathology reports noted perihilar, collapsing, or cellular lesions that characterize some subtypes of FSGS. Thus, these biopsies would be categorized as "FSGS, not-otherwise-specified" following one widely adopted classification scheme[@R5].

We examined the expression of *INF2* in the kidney by in situ hybridization and by antibody staining ([Figure 4a,b](#F4){ref-type="fig"}). Both showed *INF2* expression in the podocyte. We examined expression of INF2 and the slit-diaphragm protein nephrin together ([Figure 4b](#F4){ref-type="fig"}). INF2 expression showed areas of colocalization with nephrin in podocytes. Some INF2 staining was also noted in a pericapillary pattern, suggesting expression in cells other than podocytes. Within the podocyte, antibody staining showed what appeared to be a predominantly perinuclear pattern of INF2. Northern blot analysis showed *INF2* expression in all tissues tested and identified *INF2* transcripts of approximately 1.5 and 4.5 kb in length ([Figure 4c](#F4){ref-type="fig"}). This was consistent with previous reports describing *INF2* as well as the major transcripts predicted from ESTs and genomic sequence analysis as collated in the UCSC Genome Browser (<http://genome.ucsc.edu/>)[@R4],[@R6],[@R7].

INF2 is a member of the formin family of actin-regulating proteins that accelerate actin polymerization[@R8]. All of the FSGS-associated mutations we identified lie within the DID. The DID is an autoinhibitory domain found in the diaphanous formins. In the best studied diaphanous formin, mDia1, the interaction of the N-terminal DID with the C-terminal diaphanous activating domain (DAD) inhibits mDia1 function; this inhibition is relieved by binding to Rho [@R9]. We used structural data available for the N-terminal region of mDia1 to map the mutated INF2 residues and make functional predictions. Our INF2 model derived from the mDia1-RhoC structure ([Figure 2 c,d,e](#F2){ref-type="fig"}) was in agreement with models derived from the other available mDia1 structures (not shown)[@R10]. Two mutated residues, R214 and R218, lie close to the DAD-binding region of the DID. R214 is on the surface of the DID in proximity to this site ([Figure 2c](#F2){ref-type="fig"}). R218 is predominately buried but has a small region of surface exposure in this region ([Figure 2d](#F2){ref-type="fig"}). Three other mutated residues (L42, S186, E220) are surface-exposed but on the opposite side of the DID structure from the DAD-binding region ([Figure 2e](#F2){ref-type="fig"}). The A13 position is surface-exposed and lies at the N-terminus of the DID, in the region corresponding to the GTPase binding domain of mDia1. Two of the mutated residues are buried in the core DID structure (E184, L198).

Based on these models, we can postulate potential functions for the mutated INF2 residues. R214 and R218 likely form part of the DAD binding site, given their spatial proximity to key DAD-binding residues A149 and I152. The prominent exposure of L42, S186, and E220 on the DID surface raises the possibility that they interact with other molecules. Since the N-terminus of mDia1 plays a major role in its cellular localization[@R11], the N-terminus of INF2 could also mediate localization. We postulate that E184, L198, and R218 are likely to be important for maintaining the overall fold of the DID. These residues are buried in the interior in all of our models and the identified mutations (E184K and L198R, R218Q) could have effects on the integrity of the DID.

We inserted two mutations (E184K and R218Q) predicted to have large effects on the structural integrity of the DID into the INF2 cDNA. We also inserted a third mutation located away from the DAD binding site (S186P) into the cDNA. These three mutations included the two (E186P and R218Q) found in the large families used in the initial genetic linkage analysis. We examined cultured podocytes transfected with wild-type or mutant INF2 (E184K, S186P, and R218Q, [Figure 5](#F5){ref-type="fig"}). Wild-type transfected podocytes showed perinuclear INF2 staining, while INF2 harboring E184K and R218Q mutations showed a different localization pattern, with a finer, more diffuse distribution. The cellular localization of the S186P mutant INF2 was closer to the pattern observed in the wild-type cells but with a more vermiform appearance. Both the wild-type and mutant forms of INF2 showed significant costaining with phalloidin, consistent with the notion that these proteins induced actin polymerization at their localization, with the overall staining of phalloidin mimicking that of INF2. In the mutant transfected cells, stress fibers and cortical actin were less prominent. The similar and more dramatic changes seen with the E184K and R218Q mutants are consistent with the predicted effect on the overall INF2 DID structure. Furthermore, these data suggest that the DID domain is critical for the subcellular localization of INF2, and is consistent with data demonstrating that it is not required for the ability of INF2 to mediate actin polymerization[@R7]. While these mutant forms of INF2 clearly behave differently than the wild-type, the relationship between this altered behavior and the disease mechanism remains to be clarified.

The cumulative evidence we have presented demonstrates that mutations in the *INF2* gene cause an autosomal dominant form of FSGS. In two large families, we found evidence of genetic linkage to a region on chromosome 14 containing *INF2*. We identified missense mutations in *INF2* in 11 of 93 families examined. These mutations cause non-conservative substitutions in amino acids that are highly conserved through evolution. Within the individual families harboring these mutations, inheritance of the mutation segregates with disease. Seven of the nine distinct mutations occur in close proximity within exon 4, and all nine lie within the diaphanous inhibitory domain. By resequencing, we verified that neither these mutations, nor other non-synonymous DID variants, are present in control groups.*INF2* is highly expressed in the kidney including in glomerular podocytes, the cell type thought to initiate most forms of FSGS. Electron microscopy of kidney biopsy material from an *INF2*-mutant FSGS patient showed irregular podocyte foot process morphology and prominent actin bundles. In addition, transfection studies of overexpressed wild-type and FSGS-associated mutant forms of *INF2* indicate differences in the subcellular localization of mutant and wild-type protein, as well as differences in the pattern of distribution of the associated F-actin. In the electron micrographs, prominent actin filament bundles are noted, whereas actin filaments appear somewhat less prominent than normal in the INF2-mutant expressing cells. The precise mechanism by which actin behavior is disrupted in the presence of INF2 mutations *in vivo* remains to be defined.

Formins are a family of proteins that accelerate actin filament assembly[@R12]. INF2 has the unique ability to accelerate both polymerization as well as depolymerization of actin *in vitro*, and localizes to the endoplasmic reticulum in fibroblasts. All of the disease-causing *INF2* mutations we identified are located within the N-terminal regulatory portion containing the DID[@R7]. The DID binds the DAD region of INF2 and autoinhibits INF2-mediated actin depolymerization but not actin polymerization[@R7]. Previously published work shows that expression of an INF2 mutant in which the DID/DAD interaction is blocked causes actin filament accumulation around the ER and collapse of the ER onto the nuclear membrane[@R7]. Here, we find that mutations in the DID predicted to severely affect the domain structure (E184K, R218Q) do not appear to prevent INF2 mediated actin filament accumulation, but do alter INF2 and F-actin localization.

Podocytes are complex, actin-rich, interdigitating structures that must be able to react to a unique set of physical and chemical stresses. Dysregulation of the podocyte cytoskeleton is a common feature of glomerular disease states[@R13]. The proximal trigger leading to altered actin behavior in podocytes can derive from external signals (e.g. from the slit-diaphragm[@R14]) or internally (as seen in α-actinin-4 mutations[@R1]). Similar to what has been observed with α-actinin-4, INF2 is a widely expressed actin-binding protein which when mutated causes a podocyte-limited phenotype. Our results support a model of podocytes as dynamic structures that are extremely sensitive to alterations in the spatial or temporal regulation of the actin cytoskeleton. We hypothesize that individuals harboring disease-associated *INF2* mutations have a defect in actin-mediated podocyte structural maintenance and repair. Future studies aimed at defining how *INF2* mutations lead to disease will contribute to our understanding of podocyte biology and FSGS as well as our understanding of the common forms of kidney disease characterized by podocyte dysfunction.

METHODS {#S1}
=======

Clinical ascertainment {#S2}
----------------------

Subjects were enrolled in these studies after obtaining informed consent in accordance with a human subjects protocol approved by the Brigham and Women's Hospital. We extracted DNA from peripheral blood, measured urine microalbumin and creatinine concentrations, and obtained clinical and family history information. We reviewed medical records, kidney biopsies, and biopsy reports when available.

Genotyping {#S3}
----------

In family FGBR, we performed a genome-wide analysis using DNA samples from 31 informative family members and approximately 300 microsatellite markers from the Marshfield map using standard methodology. We computed parametric 2-point and multipoint lod scores using the FASTLINK and VITESSE programs[@R15],[@R16]. In family FGJN, we performed genome-wide linkage analysis using 250K Affymetrix SNPChips, follow-up genotyping using 14q microsatellite markers, and performed parametric multipoint linkage analysis using both LINKAGE and GENEHUNTER[@R17]. Additional genotyping of the identified variants was performed using MALDI-TOF mass spectrometry (Sequenom) at the Harvard-Partners Core Genotyping Facility.

Sequencing {#S4}
----------

Using standard Sanger sequencing methodology on an ABI 3730 machine, we sequenced PCR-amplified segments containing coding sequence and flanking splice sites of 15 genes (*INF2, ADSSL1, SIVA1, AKT1, PLD4, AHNAK2, CDCA4, GPR132, JAG2, NUDT14, BRF1, PACS2, MTA1, CRIP2, CRIP1*) from the 14q critical region in 12 individuals, 3 affected and 3 unaffected members from family FGBR and from family FGJN, followed by additional sequencing of *INF2* in family members and control individuals. (Sequencing primers are available on request.)

Structural model {#S5}
----------------

We designed structural models of INF2 using the Phyre resource from Imperial College, London [@R18]. We submitted amino acids 1--424 of mouse INF2, and recovered INF2 models based on the structural coordinates of three mDia1 N-terminal structures[@R10],[@R19],[@R20]. (The fourth mDia1 N-terminal structure [@R21] was not represented in this search.) We manipulated the models using the program PyMOL. In the model, the identified FSGS mutations correspond to residues in mDia1 in the structural alignment (see [Supplementary Table](#SD1){ref-type="supplementary-material"}).

INF2 mutagenesis {#S6}
----------------

We obtained a clone containing full-length *INF2* in the pCMV6-XL5 vector (Origene). Mutagenesis was carried out using the Stratagene QuikChange II kit and mutagenesis primers designed to create the E184K, S186P, and R218Q variants. All mutagenesis reactions were verified by sequencing.

INF2 expression {#S7}
---------------

### Northern blot {#S8}

A human multiple tissue Northern blot was purchased from Ambion. 5´ sense and antisense probes consisting of the first 590 basepairs of INF2 were made using α^32^P-dCTP labeling of a PCR generated fragment using Klenow (New England Biolabs NEBlot kit).

### In situ hybridization {#S9}

Non-radioactive *in situ* hybridization was performed as described[@R22], using a digoxigenin (DIG)-labeled cRNA probe that contained the first 590 bases of the INF2 sequence. Frozen sections (10µm) of human kidney tissue were cut in a cryostat and captured onto Superfrost plus microscope slides (Fisher Scientific, Pittsburgh, PA). Sections were then fixed and acetylated, and hybridized to the probe at 70°C for approximately 72 hrs (approximate concentration 100 ng/ml). Hybridized probe was visualized using alkaline phosphatase-conjugated anti-DIG Fab fragments (Roche, Indianapolis, IN) and 5-Bromo-4-chloro-3-indolyl-phosphate/Nitroblue tetrazolium (BCIP/NBT) substrate (Kierkegard and Perry Laboratories, Gaithersburg, MD). Sections were rinsed several times in 100 mM Tris, 150 mM NaCl, 20 mM EDTA pH 9.5, and coverslipped with glycerol gelatin (Sigma, St. Louis, MO). Control sections were incubated in an identical concentration of the sense probe transcript.

Microscopy studies {#S10}
------------------

### Cultured cells {#S11}

Undifferentiated human podocytes in culture (gift of Moin Saleem) were transfected with wild-type or mutant *INF2* constructs using FuGENE (Roche). We used antibody to the C-terminus of INF2 directly conjugated to Cy3 for visualizing wild-type and mutant INF2 protein at 1:200 dilution [@R7]. We used FITC Phalloidin and DAPI to visualize actin filaments and nuclei.

### Kidney sections {#S12}

We made 5 micron sections of acetone fixed kidneys from healthy 6 week old mice. After washing with phosphate-buffered saline, we incubated sections with primary antibodies: rabbit anti-INF2 (C-terminal 300 amino acids)[@R7], guinea pig anti-nephrin (Progen Biotechnik). We used anti-rabbit Cy2 coupled and anti-guinea pig Cy3 coupled secondary antibodies to visualize INF2 and nephrin and DAPI to visualize nuclei. We analyzed specimens using a Nikon TE-200E inverted microscope and AutoDeblur deconvolution software (Media Cybernetics).
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![Pedigrees\
Pedigree diagrams of families FGBR and FGJN. Pedigree identifier and the specific mutations segregating in each family are shown.](nihms159577f1){#F1}

![INF2 mutations\
a. Disease-segregating INF2 mutations shown aligned with wild-type INF2 protein sequence from humans, chimpanzee, mouse, rat, opossum, and zebrafish. All of these disease mutations occur in evolutionarily conserved residues within the DID.\
b. Schematic showing INF2 protein domain structure and location of mutations.\
c, d, and e: Model of mouse INF2 amino acids 1--330, based on the structure of mDia1 (1). Mutated residues are shown in red, and residues important for the interaction with DAD are shown in blue.\
c. View of mDia1 showing the positions of A13 and R218 (red). Residues important for the direct interaction with DAD are shown in blue, including R106 (corresponding to K213 in mDia1), N110 (corresponding to N217 in mDia1), A149 (corresponding to A256 in mDia1), and I152 (corresponding to I259 in mDia1). Based on the crystal structure of the mDia1 DID/DAD complex (reference [@R22]), the alpha helical INF2 DAD is predicted to lie in the pocket containing these residues, with its N-terminus (D974) contacting R106 and N110, and L986 contacting A149 and I152. In this model, we predict that R218 would contact residues C-terminal to L986.\
d. Close-up of the portion of the INF2 region predicted to interact with the DAD.\
e. 180 degree rotation of the structure shown in F1, showing L42, S186, and E220.](nihms159577f2){#F2}

![Histopathology\
a, b: Kidney biopsy findings in an affected member of family FSB with an E220K INF2 mutation. This patient was 21 years of age at the time of biopsy with an estimated glomerular filtration rate (GFR) of 96 ml/min/1.73m^2^. She had 3+ urine protein and no hematuria. She developed ESRD seven years after the biopsy was performed. a. Light micrograph (PAS) showing focal global and segmental glomerulosclerosis. b. Electron micrograph showing segmental foot process effacement in some loops (arrowheads) and focally irregular morphology of preserved foot processes. Inset: Higher magnification electron micrograph showing foot processes en face, projecting from a major process. The foot processes appear irregular and jagged, often with prominent longitudinal actin bundles. c, d: Kidney biopsy findings from a different *INF2* mutant patient with an R218Q mutation, from family FGJN. This patient was 26 years old at the time of biopsy. Estimated GFR was 46 ml/min/1.73m^2^ and urine showed 3+ protein and trace blood at the time. c: Light micrograph (PAS) showing focal and segmental glomerulosclerosis, with moderate chronic parenchymal damage. d: Electron micrograph showing segmental foot process effacement (arrowheads).](nihms159577f3){#F3}

![INF2 expression\
a. RNA in situ hybridization in adult human kidney with digoxigenin-labeled probe targeted against *INF2* mRNA, followed by immunohistochemical staining with labeled antibody to digoxigenin. *INF2* mRNA expression is apparent in podocytes as well as some tubule cells. Sense control experiment is shown on the right. b. Immunofluoresence staining of mouse kidney with DAPI (blue) and antibodies against nephrin (red) and INF2 (green). INF2 staining is observed in the glomeruli in an epithelial cell pattern. Arrows show areas of nephrin and INF2 colocalization. Arrowhead shows a cell expressing INF2 but not nephrin. d. Northern blot. Gel lanes: 1, Brain; 2, Placenta; 3, Skeletal muscle; 4, Heart; 5, Kidney; 6, Pancreas; 7, Liver; 8, Lung; 9, Spleen; 10, Colon.](nihms159577f4){#F4}

![Expression of INF2 variants\
Localization of INF2 variants in undifferentiated cultured human podocytes. Cells were cultured on coverslips coated with type I collagen. INF2 is visualized using a Cy3 conjugated antibody against its C-terminus [@R7]. FITC phalloidin was used to stain F-actin, and nuclei are stained with DAPI. First column: cells expressing wild-type and three different mutant forms of INF2. Second column: INF2 channel. Third column: Phalloidin. Rows: results for WT and three mutant forms of INF2: E184K, S186P, and R218Q. E184K and R218Q mutants show diffuse localization of INF2 and F-actin compared with the perinuclear INF2 staining seen with the WT expressing cells. The S186P looked similar to WT expressing cells, but INF2 expression was more vermiform in appearance. In all three mutants, stress fibers and cortical actin appeared to be less prominent.](nihms159577f5){#F5}

  -----------------------------------------------------------------------------------
  Family   Ethnicity (Geography)     Mutation   Age range\        Age range\
                                                at diagnosis\     at ESRD\
                                                (n = number of\   onset\
                                                affecteds)        (n = number with\
                                                                  ESRD)
  -------- ------------------------- ---------- ----------------- -------------------
  FGBR     Caucasian (Canada)        S186P      12--67 (n=19)     32--67 (n=6)

  FGDM     Caucasian (Ireland/USA)   L198R      13--18 (n=2)      21--29 (n=2)

  FGEA     African-American (USA)    R218W      27--33 (n=3)      30--40 (n=2)

  FGEF     Caucasian (USA)           R214H      19--35 (n=5)      49 (n=1)

  FGEP     Caucasian (USA)           L42P       11--13 (n=3)      13--14 (n=3)

  FGER     Caucasian (Canada)        S186P      13--60 (n=9)      20--50 (n=6)

  FGFG     Caucasian (USA)           R214H      12--72 (n=7)      17--60 (n=3)

  FGGN     Latino (Mexico)           A13T       21 (n=1)          n=0

  FGGY     African-American (USA)    E184K      17--30 (n=8)      17--30 (n=7)

  FGJN     Caucasian (USA)           R218Q      22--45 (n=10)     30--45 (n=4)

  FSB      Caucasian (USA)           E220K      13--21 (n=5)      23--30 (n=4)
  -----------------------------------------------------------------------------------
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